Andrea Schulze

机构：Bayer (Germany) · ORCID：0000-0001-9035-7895

发表论文 63 篇 · 总被引 2233 次 · h-index 20

代表论文

• Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial (2024 · The Lancet · 被引 261)
• The 11-year long-term follow-up study from the randomized BENEFIT CIS trial (2016 · Neurology · 被引 131)
• Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial (2024 · The Lancet · 被引 130)
• Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial (2022 · American Journal of Obstetrics and Gynecology · 被引 52)
• Two-colour single-molecule photoinduced electron transfer fluorescence imaging microscopy of chaperone dynamics (2021 · Nature Communications · 被引 34)
• Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration (2025 · Ophthalmology · 被引 31)